Fukuoka, Shota
Koga, Yoshikatsu
Yamauchi, Mayumi
Koganemaru, Shigehiro
Yasunaga, Masahiro
Shitara, Kohei
Doi, Toshihiko
Yoshino, Takayuki
Kuronita, Toshio
Elenbaas, Brian
Wahra, Pamela
Zhang, Hong
Crowley, Lindsey
Jenkins, Molly H.
Clark, Anderson
Kojima, Takashi
Article History
Received: 24 January 2023
Accepted: 14 August 2023
First Online: 25 September 2023
Competing interests
: T.Ko.: research funds (Astellas, Bristol-Myers Squibb, MSD, Oncolys BioPharma, Ono Pharmaceutical, Shionogi, TAIHO PHARMACEUTICAL CO., LTD., BeiGene Ltd., CHUGAI PHARMACEUTICAL CO.,LTD., AstraZeneca K.K.) K.S.: lecture/conference attendance fees (Astellas Pharma) and research funds (Astellas Pharma, Lilly, Ono Pharmaceutical, Dainippon Sumitomo Pharma, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharma, MSD, Medi Science. Amgen, Eisai, and Linical Co., Ltd.). T.D.: lecture/conference attendance fees (Sumitomo Dainippon, Taiho, Takeda, Chugai Pharma, Abbvie, Bayer, Rakuten Medical, Otsuka Pharma, KAKEN Pharma, KYOWA KIRIN, SHIONOGI, PRA Health Science, A2 Health Care, Noil Immune, BMS, Ono Pharma, Daiichi Sankyo, AstraZeneca, MSD, Amgen, Novartis, Boehringer Ingelheim, Janssen Pharma, Bayer, Astellas Pharma), research funds (Lilly, MSD, Daiichi Sankyo, Sumitomo Dainippon, Taiho, Novartis, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Janssen Pharma, Boehringer Ingelheim, Pfizer, BMS, Abbvie, Eisai, IQVIA, Chugai Pharma, SHIONOGI). T.Y.: lecture/conference attendance fees (Ono Pharmaceutical, Chugai Pharmaceutical, Eli Lilly Japan, Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, Bayer, MSD, and Taiho Pharmaceutical) and research funds (Chugai Pharmaceutical, Sanofi, Daiichi Sankyo, Parexel International, Ono Pharmaceutical, Pfiizer, Taiho Pharmaceutical, MSD, Amgen, Genomedia, Sysmex and Boehringer Ingelheim). M.Y.: research funds (Daiichi Sankyo, Sumitomo Dainippon Pharma, Novartis, and Bristol-Myers Squibb). B.E., P.W., H.Z., M.H.J., and A.C.: employees of EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA, at the time the studies were conducted. T.Ku. an employee of Merck Biopharma Co., Ltd., Tokyo, Japan, an affiliate of Merck KGaA, at the time the studies were conducted and now an employee of Daiichi Sankyo Co., Ltd. No other authors have Conflict of Interest.